Source: Ophthalmology
Area: News
One-year results from the DA VINCI Phase II study evaluating aflibercept (VEGF Trap-Eye versus photocoagulation in the treatment of diabetic macular oedema (DMO) have been published early online in Ophthalmology.
The study included 221 patients with centre-involved DMO who were randomised to one of four dosing regimens of aflibercept (0.5mg every four weeks; 2mg every four weeks; 2mg every eight weeks after three monthly doses; 2mg as need after three monthly doses) or macular laser photocoagulation. The primary endpoint was change in best-corrected visual acuity (Read more...)
Uncategorized